drugset / Trial / NCT00003476

Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors

NCT00003476

Phase 2 Terminated 8 enrolled Burzynski Research Institute
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Current therapies for children with primary malignant brain tumors provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of children with primary malignant brain tumors. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on children with primary malignant brain tumors.

Timeline

Start
1996-03
Primary completion
2012-01
Completion
2012-01

Publications

  • Background Burzynski SR, Janicki TJ, Burzynski GS, Marszalek A, Brookman, S. A phase II study of Antineoplastons A10 and AS2-1 in children with recurrent, refractory or progressive primary brain tumors - Final Report (Protocol BT-22). Journal of Cancer Therapy, 5:977-988, 2014.

Drugs

EvaluationDrugModalityDoseRoute
Subject Astugenal Unknown Intravenous
Subject antineoplaston A10 Small molecule Intravenous

Indications